The reimbursement factor in pharmaceutical regulation: rebates, cost-effectiveness, and practice guidelines.

摘要: The delivery of health care services in the United States is increasingly influenced by coverage determinations third—party payers. This paper reviews 3 specific initiatives recently undertaken federal government that relate directly or indirectly to reimbursement for pharmaceuticals. initiatives, involving new conditions and incorporating language policies signal broader changes future, are Medicaid Prudent Pharmaceutical Purchasing Program enacted as part Omnibus Budget Reconciliation Act 1990, national criteria proposed Health Care Financing Administration, Agency For Policy Research with its mandate oversee development clinical practice guidelines.